Zoledronate Every 5 Years Reduced Vertebral Fractures in Early Postmenopausal Women
In early postmenopausal women aged 50 to 60 years, zoledronate at baseline and 5 years reduced 10-year morphometric vertebral fractures from 11.1% to 6.3%.
Hormone Insight
Evidence summaries in diabetes, endocrinology, and metabolism for clinicians who need the key data fast.
Latest Evidence
View all PICO summaries
Dapagliflozin Plus Calorie Restriction Increased Type 2 Diabetes Remission in Early Disease
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.
IoN Trial: Radioiodine Could Be Avoided After Surgery for Low-Risk Thyroid Cancer
In the IoN non-inferiority RCT, omitting postoperative radioiodine after total thyroidectomy produced 5-year recurrence-free survival of 97.9% versus 96.3% with ablation in selected low-risk thyroid cancer.
REDEFINE 1: CagriSema Produced 20.4% Weight Loss in Adults Without Diabetes
In REDEFINE 1, once-weekly cagrilintide-semaglutide produced 20.4% mean weight loss at 68 weeks versus 3.0% with placebo in adults with overweight or obesity without diabetes.
Automated Insulin Delivery Improved HbA1c and Time in Range in Type 2 Diabetes
In insulin-treated type 2 diabetes, automated insulin delivery reduced HbA1c by an adjusted 0.6 percentage points and increased time in range by 14 points versus CGM with usual insulin delivery.
CONFIDENCE: Finerenone Plus Empagliflozin Reduced Albuminuria More Than Either Drug Alone
In CKD with type 2 diabetes and albuminuria, simultaneous finerenone plus empagliflozin reduced UACR more than either treatment alone at 180 days, without unexpected safety findings.
REDEFINE 2: CagriSema Reduced Weight and HbA1c in Type 2 Diabetes
In REDEFINE 2, CagriSema reduced weight by 13.7% versus 3.4% with placebo at 68 weeks, and 73.5% achieved HbA1c <=6.5% in adults with type 2 diabetes.
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL)
In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.